MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurjpc/zwag421

Медицинская библиотека · European journal of preventive cardiology · 2026

Medication persistence and mortality in ST-elevation myocardial infarction patients with and without standard modifiable risk factors: a SWEDEHEART registry study.

Avis Suzanne R, Hadziosmanovic Nermin, Gray Michael P, Vernon Stephen T, Buckley Thomas, Leósdóttir Margrét, Alfredsson Joakim, Chow Clara K, Hagstrom Emil, Figtree Gemma A

СтатьяПеревод в очереди

Аннотация

AIMS: We examine persistence with secondary prevention medication and longer-term mortality in a population-level cohort of ST-elevation myocardial infarction (STEMI) patients with and without standard modifiable cardiovascular risk factors (SMuRFs; hypertension, diabetes, hypercholesterolaemia, smoking).

METHODS AND

RESULTS

We utilized landmark analysis to study 65 059 first-time STEMI patients from the SWEDEHEART registry who were prescribed aspirin, lipid-lowering therapy (LLT), renin-angiotensin-aldosterone system (RAAS) inhibitors, or beta-blockers at hospital discharge. Persistence was assessed as a binary variable in patients alive 12 months after first dispensation (initiation, the landmark). The primary outcome was all-cause mortality 3 years after the 12-month landmark. Multivariable logistic regression models and Kaplan-Meier analyses were used to compare persistence, and Cox proportional hazards models to assess the impact of persistence on mortality. At 4 years after pharmacotherapy initiation, >50% of patients had discontinued prescribed aspirin, LLT, RAAS inhibitor, or beta-blocker. SMuRF-less patients were less likely to receive medications at hospital discharge; however, if prescribed, they were more likely to be persistent with aspirin and LLT at 12 months compared to SMuRF-positive patients. Discontinuing aspirin, LLT, or RAAS inhibitors within 12 months after initiation was associated with increased all-cause mortality 3 years later in both groups (HR between 1.45 and 2.02). Beta-blocker discontinuation was not associated with mortality in either group.

CONCLUSION

Persistence with secondary prevention medication declined rapidly in this cohort. The increased longer-term mortality associated with 12-month non-persistence highlights the need to better understand drivers of medication discontinuation, and to work with patients and clinicians to support consistent use of guideline-recommended medications, regardless of risk factor status.

Для цитирования: Avis Suzanne R, Hadziosmanovic Nermin, Gray Michael P, Vernon Stephen T, Buckley Thomas, Leósdóttir Margrét, Alfredsson Joakim, Chow Clara K, Hagstrom Emil, Figtree Gemma A. Medication persistence and mortality in ST-elevation myocardial infarction patients with and without standard modifiable risk factors: a SWEDEHEART registry study.. European journal of preventive cardiology. 2026. DOI: 10.1093/eurjpc/zwag421.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.